Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth M Holland

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Pediatric Blood & Cancer|May 28, 2025
How I Approach Ethical Considerations for Pediatric Phase I CAR T-Cell TrialsSarah W Peters, Sara K Silbert, Elizabeth M Holland, et al.
Blood Advances|July 24, 2023
A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trialsSara K Silbert, Sanna Madan, Elizabeth M Holland, et al.
Blood Advances|December 17, 2021
Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapyElizabeth M Holland, Bonnie Yates, Alex Ling, et al.
Transplantation and Cellular Therapy|July 2, 2023
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell FailureElizabeth M Holland, Bonnie Yates, Seth M Steinberg, et al.
Frontiers in Immunology|January 3, 2022
Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-CellsElizabeth M Holland, Corina Gonzalez, Elliot Levy, et al.
Journal for Immunotherapy of Cancer|May 9, 2022
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulationElizabeth M Holland, John C Molina, Kniya Dede, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Pediatric Blood & Cancer|May 28, 2025
How I Approach Ethical Considerations for Pediatric Phase I CAR T-Cell TrialsSarah W Peters, Sara K Silbert, Elizabeth M Holland, et al.
Blood Advances|July 24, 2023
A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trialsSara K Silbert, Sanna Madan, Elizabeth M Holland, et al.
Blood Advances|December 17, 2021
Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapyElizabeth M Holland, Bonnie Yates, Alex Ling, et al.
Transplantation and Cellular Therapy|July 2, 2023
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell FailureElizabeth M Holland, Bonnie Yates, Seth M Steinberg, et al.
Frontiers in Immunology|January 3, 2022
Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-CellsElizabeth M Holland, Corina Gonzalez, Elliot Levy, et al.
Journal for Immunotherapy of Cancer|May 9, 2022
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulationElizabeth M Holland, John C Molina, Kniya Dede, et al.
Pageof 1